Roche Pushes Ahead Late-Stage Pipeline Drugs to Stay In Front of Competition

Noticing biosimilar competition on the horizon, Roche Holding (OTCMKTS:RHHBY)(VTX:ROG) is aggressively pushing ahead with its late-stage pipeline drugs. In particular, Roche is placing its best on a PD-L1 cancer drug atezolizumab.
According to the article on Fierce Biotech:

Roche is late to the immuno-oncology market. An aggressive Merck (NYSE:MRK) has been jockeying with market leader Bristol-Myers Squibb (NYSE:BMY) in the drive on landmark approvals, riding their drug Keytruda as Bristol-Myers pushes Opdivo toward more regulatory successes. Those are PD-1 drugs, though, giving Roche a shot at first-mover status on the PD-L1 side of IO, which is dismantling cancer cells’ cloak of invisibility and unleashing an immune system assault.

 
Click here to read the full article on Fierce Biotech.